Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer

@article{Poon2009LysothermosensitiveLD,
  title={Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer},
  author={Ronnie T. P. Poon and Nicholas J. Borys},
  journal={Expert Opinion on Pharmacotherapy},
  year={2009},
  volume={10},
  pages={333 - 343}
}
  • R. Poon, N. Borys
  • Published 20 January 2009
  • Medicine, Biology
  • Expert Opinion on Pharmacotherapy
Background: Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer death worldwide. No more than 30% of HCC patients receive curative treatment. Factors limiting curative therapy include tumor size and degree of liver impairment. Objective: To develop a cure for medium (3.1 – 5.0 cm) and large ( > 5 cm) tumors in seriously impaired livers. Method: Combine radiofrequency ablation (RFA) with lyso-thermosensitive liposomal doxorubicin (LTLD). Results/conclusions: RFA is used safely… 
RFA plus lyso-thermosensitive liposomal doxorubicin: in search of the optimal approach to cure intermediate-size hepatocellular carcinoma.
TLDR
The OPTIMA study is currently ongoing to test the hypothesis that adding LTLD to a standardized RFA lasting ≥45 min increases survival compared withStandardized RFA alone.
Old versus New – Tumor Ablation versus Tumor Nanoablation with Particular Emphasis on Liver Tumors
TLDR
There are many ways to induce nanoparticle mediated thermal therapy in solid tumors including absorption of infrared light, radiofrequency ablation and magnetically induced heating and these approaches have demonstrated high efficacy in preclinical models of HCC and are already tested in human clinical trials.
Increased Duration of Heating Boosts Local Drug Deposition during Radiofrequency Ablation in Combination with Thermally Sensitive Liposomes (ThermoDox) in a Porcine Model
TLDR
The purpose of this study was to optimize the RFA procedure used in combination with LTLD to maximize the local deposition of doxorubicin in a swine liver model and to reduce recurrence and be more effective than thermal ablation alone.
A novel two-step mild hyperthermia for advanced liposomal chemotherapy.
  • Li Li, T. T. ten Hagen, G. Koning
  • Biology, Engineering
    Journal of controlled release : official journal of the Controlled Release Society
  • 2014
Longer heating duration increases localized doxorubicin deposition and therapeutic index in Vx2 tumors using MR-HIFU mild hyperthermia and thermosensitive liposomal doxorubicin
  • Chenchen Bing, P. Patel, Rajiv Chopra
  • Engineering
    International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  • 2019
TLDR
Results from this preclinical study can be used to help establish clinical treatment protocols for hyperthermia mediated drug delivery and an increased duration of heating leads to higher Dox deposition from LTSL-Dox in a target tumor without a concomitant increase in systemic exposure.
Tumor Drug Distribution after Local Drug Delivery by Hyperthermia, In Vivo
TLDR
Investigation of tumor drug distribution after treatment with various injected doses of different liposomal formulations of doxorubicin, ThermoDox (temperature sensitive liposomes) and DOXIL (non-temperaturesensitive liposome) indicates that tumorDrug distribution is an important factor for effective tumor treatment and that its dependence on delivery formulation merits further systemic investigation.
Hyperthermia-triggered drug delivery from temperature-sensitive liposomes using MRI-guided high intensity focused ultrasound.
  • H. Grüll, S. Langereis
  • Biology
    Journal of controlled release : official journal of the Controlled Release Society
  • 2012
...
...

References

SHOWING 1-10 OF 97 REFERENCES
Radiofrequency ablation of hepatic tumors: increased tumor destruction with adjuvant liposomal doxorubicin therapy.
TLDR
The authors' pilot clinical study suggests that adjuvant Doxil chemotherapy increases tumor destruction compared with radiofrequency ablation therapy alone in a variety of focal hepatic tumors.
Combination radiofrequency thermal ablation and adjuvant IV liposomal doxorubicin increases tissue coagulation and intratumoural drug accumulation
  • M. Ahmed, S. Goldberg
  • Medicine, Biology
    International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  • 2004
There has been marked interest in minimally-invasive, image-guided radiofrequency (RF) tumour ablation (i.e. coagulating tumour using short duration heating (<15 min) by directly applying
Liposomal Doxorubicin Combined with Regional Hyperthermia: Reducing Systemic Toxicity and Improving Locoregional Efficacy in the Treatment of Solid Tumors
TLDR
Pegylated liposomal doxorubicin (PLD) is an established therapeutic agent in epithelial ovarian carcinoma, breast carcinoma or Kaposi’s sarcoma, and PLD administration results in reduction of toxicity.
Radiofrequency thermal ablation sharply increases intratumoral liposomal doxorubicin accumulation and tumor coagulation.
TLDR
Combining radiofrequency (RF) ablation with i.v. liposomal doxorubicin (Doxil) increases intratumoral doxorbicin accumulation and tumor destruction and also increases tumor destruction over either therapy alone.
Combined radiofrequency ablation and adjuvant liposomal chemotherapy: effect of chemotherapeutic agent, nanoparticle size, and circulation time.
TLDR
When combined with RF ablation, modification of adjuvant intravenous liposomal chemotherapy, including nanoparticle size, circulation time, and chemotherapeutic agent, can influence intratumoral drug accumulation and tissue coagulation.
Combination radiofrequency ablation with intratumoral liposomal doxorubicin: effect on drug accumulation and coagulation in multiple tissues and tumor types in animals.
PURPOSE To determine whether use of radiofrequency (RF) ablation combined with intravenously (IV) administered liposomal doxorubicin, as compared with use of RF ablation or doxorubicin alone,
Pegylated Liposomal Doxorubicin in Combination With Hyperthermia in the Treatment of a Case of Advanced Hepatocellular Carcinoma
TLDR
This report may be the first report of the combination of pegylated liposomal doxorubicin and hyperthermia in the treatment of advanced hepatocellular carcinoma and suggests that the combination is technically feasible, well tolerated, and could have synergistic potential.
Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm.
TLDR
RF ablation yielded better clinical outcomes than conventional and higher-dose PEI in treating HCC 4 cm or less andMultivariate analysis determined that tumor size, tumor differentiation, and the method of treatment (RF vs both methods of PEI) were significant factors in relation to local tumor progression, overall survival, and cancer-free survival.
Efficacy of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma
TLDR
PLD can be delivered safely in patients with aHCC and no signs of moderate hepatic failure and future studies on systemic chemotherapy should focus on patients without moderate hepatics failure, with WHO PS <2, and with liver tumour involvement <50%.
Phase I Trial of Doxorubicin-Containing Low Temperature Sensitive Liposomes in Spontaneous Canine Tumors
TLDR
LTSL-doxorubicin offers a novel approach to improving drug delivery to solid tumors and was well tolerated and resulted in favorable response profiles in these patients.
...
...